Design, synthesis and evaluation of diclofenac-antioxidant mutual prodrugs as safer NSAIDs

Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry

Volumn 48, Issue 9, 2009, Pages 1279-1287

  Manon, Benu ^a   Sharma, Pritam D ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Antioxidants; Diclofenac; Mutual prodrug; NSAIDs; Ulcerogenicity

Indexed keywords

EID: 70350029233     PISSN: 03764699     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Clive D M & Stoff J S, N Engl J Med, 310, 1984, 563.
2. Johnson A G, Drug Saf, 17, 1997, 277.
3. Perez G S, Garcia R L A. Rainford D S, Duque O A & Ris R J, Arc intern Med, 156, 1996, 2433.
4. Polonia J. J Cardiol, 88, 1997, 47.
5. Vane J R. Nat New Bio. 231. 1971, 232.
6. Vane J R & Botting R M, Inflam Res, 44, 1995, 1.
7. Hla T & Neilson K, Proc Natl Acad Sci USA, 89, 1992, 7384.
8. Mcadc E A. Smith W L & DeWitt D L, J Biol Chem, 268, 1993, 6610.
9. Xie W. Robertson D L & Simmons D L, Drug Dev Res, 25, 1992. 249.
10. Cao C, Matsumura K, Yamagata K & Watanabe Y, Brain Res, 733. 1996, 263.
11. Reuter B K. Asfaha S. Buret A. Sharkey K A & Wallace J L, J Clin Invest. 98, 1996, 2076.
12. Warner T D. Giuliano F. Vojnovic I, Bukada A, Mitchell J A & Vane J R. Proc Natl Acad Sci USA. 96, 1999, 7563.
13. Roth R N & Weiss L D. Clin Dermatol, 12, 1994, 141.
14. Yoshikawa T. Naito Y, Kishi A, Tomii T, Kaneko T, Iinuma S. Ichikawa H. Yasuda M, Takahashi S & Kondo M, Gut, 34, 1993, 732.
15. Brzozowski T, Konturek P C, Konturck S J, Pajdo R, Biclanski W, Brzozowska I, Stachura J & Hahn E G, J Pineal Res. 23, 1997, 79.
16. Vaananann D M. Medding J B & Wallace J L. Am J Physiol, 261, 1991, G470.
17. Ivey K .J. Am J Med. 84, 1988, 41.
18. Nakatani M. Biofactors. 13, 2000, 141.
19. Alcaraz M J & Jimenez M J, Fitoterapia, 1, 1988, 25.
20. Chatterjee G K & Pal S K, Indian Drugs, 21, 1984, 413.
21. Singh G & Sharma P D, Indian J Pharm Sci, 56, 1994, 69.
22. Leppanen J, Huuskonen J, Ncvalaincn T, Gynthcr J, Taipalc H & Jürvinen T, J Med Chem, 45, 2002, 1379.
23. Albert A, Nature, 182, 1958, 42.
24. Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities. Design of Prodrugs, edited by H Bundgaard (Elsevier Science Publisher. Netherland) 1985, p. 1.
25. Cotelle N, Curr Top Med Chem, 1, 2001, 569.
26. Vaya J & Aviram M, Curr Med Chem. 1, 2001, 99.
27. Gordon M, Nat Prod Rep, 13, 1996, 265.
28. Sharma P D, Kaur G, Kansal S & Chandiran S, Indian J Chem, 43B, 2004, 2159.
29. Winter C A, Risley G A & Nuss G W, Proc Soc Exp Biol Med, 3, 1962, 544.
30. Koster R, Anderson M & De Beer E J, Fed Proc, 18, 1959, 412.
31. Jain N K, Patil C S, Kartasasmita R E, Decker M & Lehmann J, Drug Dev Res, 61, 2004, 66.
32. Vogel's Textbook of Practical Organic Chemistry, edited by B S Furniss, A J Hannaford, PWG Smith and A R Tatchell (Pearson Education, Singapore) 2005, p. 395.